EPA Ethyl Ester Therapy for AF Patients With High Triglycerides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for cardiovascular diseases, such as Lovaza®, can increase LDL-C and/or non-HDL-C levels in some patients, and there is a need for improved methods to manage triglyceride levels in individuals with atrial fibrillation and/or atrial flutter.
Innovation Solution
Administering eicosapentaenoic acid (EPA) or its derivatives to patients with triglyceride levels above 150 mg/dl, considering individual risk profiles to balance the risk of atrial fibrillation/flutter against cardiovascular benefits, and potentially combining with statins for personalized treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Lovaza (EPA) is administered to reduce triglyceride levels, then triglyceride levels are reduced, but LDL-C and/or non-HDL-C levels increase
Solution Approach 1:
The patent applies parameter changes by carefully monitoring and adjusting triglyceride reduction targets to achieve a balance where triglyceride levels are reduced without causing excessive increases in LDL-C and non-HDL-C. The system evaluates multiple lipid parameters simultaneously and modifies treatment parameters to optimize the lipid profile overall.
Solution Approach 2:
The patent implements feedback mechanisms through continuous monitoring of lipid levels (triglycerides, LDL-C, non-HDL-C) and adjusts EPA administration accordingly. The system uses feedback from lipid panel results to determine whether to continue, modify, or discontinue treatment, ensuring that triglyceride reduction does not lead to harmful increases in other lipid parameters.
2Reliability
If EPA is administered to patients with atrial fibrillation history, then cardiovascular events are reduced, but atrial fibrillation symptoms may increase
Solution Approach 1:
The patent uses feedback from monitoring atrial fibrillation symptoms and cardiovascular events to dynamically adjust EPA administration. The system evaluates whether the reduction in cardiovascular events outweighs the increase in atrial fibrillation symptoms and modifies treatment accordingly, allowing for personalized risk-benefit assessment.
Solution Approach 2:
The patent applies dynamics by making the treatment approach adaptive and flexible rather than static. The system continuously reassesses the risk-benefit ratio as patient conditions change over time, adjusting EPA dosage or discontinuing treatment when atrial fibrillation symptoms become problematic, while maintaining cardiovascular protection when benefits outweigh risks.
3Quantity of substance
If aggressive triglyceride reduction is pursued, then triglyceride levels decrease, but risk of atrial fibrillation/flutter increases
Solution Approach 1:
The patent applies parameter changes by establishing optimal target ranges for triglyceride reduction that balance cardiovascular benefit against atrial fibrillation risk. Rather than pursuing maximum triglyceride reduction, the system identifies and maintains triglyceride levels within a therapeutic window that provides cardiovascular protection without triggering arrhythmias.
Solution Approach 2:
The patent converts the potential harm of triglyceride reduction (increased atrial fibrillation risk) into a benefit by carefully controlling the reduction process. The system uses monitoring and adjustment to ensure that triglyceride levels are reduced to beneficial levels without crossing the threshold that would cause harmful arrhythmias, effectively turning a potentially harmful process into a beneficial one.
Data Source
AI summary
In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and/or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.